134 related articles for article (PubMed ID: 678452)
21. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
Garbelli S; Mantovani S; Palermo B; Giachino C
Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
[TBL] [Abstract][Full Text] [Related]
22. [Characterization of antigens reacting with vitiligo and cytoplasmic melanoma antibodies].
Presser HJ; Morenz J; Höfs T; Zugehör M; Kühne KH; Brödemann M
Dermatol Monatsschr; 1987; 173(8):441-5. PubMed ID: 3311840
[No Abstract] [Full Text] [Related]
23. Vitiligo and melanoma: can genetically abnormal melanocytes result in both vitiligo and melanoma within a single family?
Lerner AB; Kirkwood JM
J Am Acad Dermatol; 1984 Oct; 11(4 Pt 1):696-701. PubMed ID: 6490994
[TBL] [Abstract][Full Text] [Related]
24. Relevance of congenital melanocytic naevi in vitiligo.
van Geel N; Van Poucke L; Van de Maele B; Speeckaert R
Br J Dermatol; 2015 Apr; 172(4):1052-7. PubMed ID: 25292332
[TBL] [Abstract][Full Text] [Related]
25. [Identification of protein S 100 and melanoma-associated antigens in a comparative study of malignant melanoma and nevus pathology].
Monti M; Berti E; Cavicchini S; Paindelli MG; Terragni L
G Ital Dermatol Venereol; 1985; 120(4):297-306. PubMed ID: 3899920
[No Abstract] [Full Text] [Related]
26. Resolution of vitiligo following excision of halo congenital melanocytic nevus: a rare case report.
Wang K; Wang Z; Huang W
Dermatol Ther; 2016 May; 29(3):145-7. PubMed ID: 26627472
[TBL] [Abstract][Full Text] [Related]
27. Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: could it be related to a different cytokine microenvironment?
Moretti S; Spallanzani A; Pinzi C; Prignano F; Fabbri P
J Cutan Pathol; 2007 Apr; 34(4):301-8. PubMed ID: 17381800
[TBL] [Abstract][Full Text] [Related]
28. Molecular evidence that halo in Sutton's naevus is not vitiligo.
Schallreuter KU; Kothari S; Elwary S; Rokos H; Hasse S; Panske A
Arch Dermatol Res; 2003 Nov; 295(6):223-8. PubMed ID: 14530988
[TBL] [Abstract][Full Text] [Related]
29. Cytoplasmic beta-catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: potential implications for melanoma tumorigenesis?
De Panfilis G; Ferrari D; Santoro S; Ricci R; Lombardi M; Pedrazzi G; Pepe C; Cortelazzi C; Santini M
Br J Dermatol; 2009 Mar; 160(3):600-8. PubMed ID: 19183173
[TBL] [Abstract][Full Text] [Related]
30. [Immunologic analysis of tyrosinase in malignant melanoma, nevi and clinically normal skin].
Herrmann WP
Arch Dermatol Forsch; 1971; 241(1):65-74. PubMed ID: 4997883
[No Abstract] [Full Text] [Related]
31. Malignant melanoma in renal-transplant recipients.
Greene MH; Young TI; Clark WH
Lancet; 1981 May; 1(8231):1196-9. PubMed ID: 6112537
[TBL] [Abstract][Full Text] [Related]
32. New perspectives on the role of vitiligo in immune responses to melanoma.
Byrne KT; Turk MJ
Oncotarget; 2011 Sep; 2(9):684-94. PubMed ID: 21911918
[TBL] [Abstract][Full Text] [Related]
33. Vitiligo and malignant melanoma.
Fodor J; Bodrogi I
Neoplasma; 1975; 22(4):445-8. PubMed ID: 1196428
[TBL] [Abstract][Full Text] [Related]
34. [Cutaneous achromia and malignant melanoma].
Barrière H; Litoux P; Le Lay M; Bureau B; Stalder JF; Dreno B
Ann Dermatol Venereol; 1984; 111(11):991-6. PubMed ID: 6524818
[TBL] [Abstract][Full Text] [Related]
35. [Delayed hypersensitivity reaction in malignant melanoma].
Gorodilova VV; Saraeva ZM; Slesareva RI; Monzul' GD
Vopr Onkol; 1973; 19(3):23-7. PubMed ID: 4762691
[No Abstract] [Full Text] [Related]
36. Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism.
Merimsky O; Shoenfeld Y; Yecheskel G; Chaitchik S; Azizi E; Fishman P
Cancer Immunol Immunother; 1994 Jun; 38(6):411-6. PubMed ID: 8205563
[TBL] [Abstract][Full Text] [Related]
37. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
[TBL] [Abstract][Full Text] [Related]
38. Antimelanoma immunity in vitiligo and melanoma patients.
Juranic ZD; Stanojevic-Bakic N; Zizak Z; Babovic N; Radovic-Kovacevic V; Stanojkovic T; Dzodic R
Neoplasma; 2003; 50(4):305-9. PubMed ID: 12937846
[TBL] [Abstract][Full Text] [Related]
39. [Nevus on nevus. Apropos of 7 case reports, 3 of them associated with other dysplasias, and 1 with an invasive malignant melanoma].
Brufau C; Moran M; Armijo M
Ann Dermatol Venereol; 1986; 113(5):409-18. PubMed ID: 3579111
[TBL] [Abstract][Full Text] [Related]
40. Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma.
Hellström I; Warner GA; Hellström KE; Sjögren HO
Int J Cancer; 1973 Mar; 11(2):280-92. PubMed ID: 4790696
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
